By

Luke Timmerman

20
May
2024

SynBio and AI for Discovery: David Younger and Randolph Lopez on The Long Run

Today’s guests on The Long Run are the co-founders of Seattle-based A-Alpha Bio — David Younger and Randolph Lopez. David is the CEO and Randolph is the chief technology officer. The company was founded in 2017 as a spinout from the University of Washington’s Institute for Protein Design. The company has built a platform for doing high-volume synthetic biology to...
Read More
20
May
2024

Timmerman Traverse Eclipses $10M for Cancer, Poverty, and Sickle Cell Disease

The Timmerman Traverse campaigns have now catalyzed the biotech community to give back more than $10 million to tackle cancer, poverty, and sickle cell disease. It’s a moment to celebrate. These biotech community drives have succeeded beyond my wildest dreams. They’ve raised awareness, corralled funds, and stitched together a network of meaningful relationships.   More than 120 people have become...
Read More
1
May
2024

Investing in Biotech & Healthcare Delivery: Vineeta Agarwala on The Long Run

Today’s guest on The Long Run is Vineeta Agarwala. Vineeta is a general partner with Andreesen Horowitz’s Bio & Health fund. She invests in a variety of therapeutics and diagnostics startups. Gate Bioscience, Rome Therapeutics, Rezo Therapeutics, Bighat Bioscience, Function Oncology, and Orbital Therapeutics are a few examples. She also is a physician by training, still sees patients once a...
Read More
10
Apr
2024

Meet the Timmerman Traverse for Sickle Forward Team

I’m thrilled to announce a new initiative to raise $1 million to fight sickle cell disease. It’s the Timmerman Traverse for Sickle Forward. A team of 21 biotech leaders are banding together for Sickle Forward in 2024. It’s a nonprofit dedicated to improving newborn screening and treatment of sickle cell disease in Africa. When we hit that goal, we will...
Read More
1 2 3 46